{"id":"inr101","safety":{"commonSideEffects":[{"rate":"null","effect":"International normalized ratio (INR) elevation"},{"rate":"10-20%","effect":"Bleeding"},{"rate":"1-5%","effect":"Gastrointestinal bleeding"},{"rate":"1-5%","effect":"Hemorrhage"},{"rate":"5-10%","effect":"Bruising"},{"rate":"1-5%","effect":"Purpura"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It achieves this by targeting the vitamin K epoxide reductase complex 1 (VKORC1), which is essential for the recycling of vitamin K in the liver. By inhibiting VKORC1, INR101 reduces the production of vitamin K-dependent clotting factors, thereby preventing blood clots.","oneSentence":"INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:20.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT06922903","phase":"PHASE3","title":"Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Yunhe Pharmaceutical (Tianjin) Co., Ltd","startDate":"2025-04","conditions":"Prostate Cancer","enrollment":240},{"nctId":"NCT06922929","phase":"PHASE3","title":"A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment","status":"NOT_YET_RECRUITING","sponsor":"Yunhe Pharmaceutical (Tianjin) Co., Ltd","startDate":"2025-04","conditions":"Prostate Cancer Recurrent","enrollment":110},{"nctId":"NCT06472531","phase":"PHASE1, PHASE2","title":"A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer","status":"COMPLETED","sponsor":"Yunhe Pharmaceutical (Tianjin) Co., Ltd","startDate":"2024-05-23","conditions":"Healthy Male Subjects, Suspected Prostate Cancer","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["INR101 PET CT"],"phase":"phase_3","status":"active","brandName":"INR101","genericName":"INR101","companyName":"Yunhe Pharmaceutical (Tianjin) Co., Ltd","companyId":"yunhe-pharmaceutical-tianjin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors. Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}